Role of IL-35 in sublingual allergen immunotherapy

Purpose of review Sublingual allergen immunotherapy (SLIT), a disease-modifying treatment for allergic rhinitis, can induce long-term clinical benefits which are mediated by immune responses that include generation of regulatory B (Breg) and T (Treg) cells. The newest member of the IL-12 superfamily, IL-35, is an anti-inflammatory cytokine known to be produced by Breg and Treg cells. Limited studies are available on the role of IL-35 on allergic rhinitis and during SLIT. This review summarizes recent findings relevant to the topic of IL-35 and their role in SLIT. Recent findings Recombinant IL-35 protein can induce the generation of IL-35-producing Breg and Treg cells with immunosuppressive capacity. Levels of IL-35 and IL-35-inducible Treg (iTR35) cells are dysregulated in allergic rhinitis patients, which can be restored with SLIT. Mechanism of IL-35-mediated tolerance to allergens includes suppressions of T cell proliferation, Th2 cytokine production, and B cell production of IgE antibodies. Summary Emerging evidence supports a potential role for IL-35 and iTR35 cells in tolerance maintenance during SLIT. A better understanding for the role of IL-35 and iTR35 cells could provide new avenues for the development of clinical biomarker to assess efficacy of allergen immunotherapy and novel therapeutic strategies for allergic rhinitis.

• Publication year

  2019

• Venue

  Current Opinion in Allergy and Clinical Immunology

• Publication date

  2019-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/ACI.0000000000000499PMID 30507716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of IL‐35 in sublingual allergen immunotherapy

  2019cited by this paper
• Recent developments and highlights in allergen immunotherapy

  2018cited by this paper
• Immunological Changes Induced in Peach Allergy Patients with Systemic Reactions by Pru p 3 Sublingual Immunotherapy

  2018cited by this paper
• Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers.

  2017cited by this paper
• Synchronous immune alterations mirror clinical response during allergen immunotherapy

  2017cited by this paper
• Regulatory B cells: Phenotype, function and role in transplantation.

  2017cited by this paper
• Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial

  2017cited by this paper
• Human regulatory B cells control the TFH cell response

  2017cited by this paper
• Interleukin-35 on B cell and T cell induction and regulation

  2017cited by this paper
• Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control.

  2016cited by this paper
• Intranasal administration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis

  2016cited by this paper
• Interleukin-35: Expanding Its Job Profile

  2015cited by this paper
• Regulatory B cells: origin, phenotype, and function.

  2015cited by this paper
• Cytokine Modulation by IL-35 in Mice with Allergic Rhinitis

  2015cited by this paper
• Clinical practice. Allergic rhinitis.

  2015cited by this paper
• IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

  2014cited by this paper
• Sublingual immunotherapy: World Allergy Organization position paper 2013 update

  2014cited by this paper
• Sublingual Immunotherapy for Asthma: Affects T-Cells but Does not Impact Basophil Activation

  2014cited by this paper
• Interleukin-35 Induces Regulatory B Cells that Suppress CNS Autoimmune Disease

  2014cited by this paper
• [Expression of IL-35, Epstein-Barr virus-induced gene 3 mRNA and IL-12A mRNA in peripheral blood of patients with allergic rhinitis].

  2014cited by this paper
• Predictive biomarkers of clinical efficacy of allergen-specific immunotherapy: how to proceed.

  2013cited by this paper
• Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report.

  2013cited by this paper
• IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses.

  2013cited by this paper
• Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy.

  2013cited by this paper
• A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy.

  2012cited by this paper
• Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes.

  2012cited by this paper
• Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy

  2012cited by this paper
• SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.

  2012cited by this paper
• Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.

  2012cited by this paper
• The composition and signaling of the IL-35 receptor are unconventional

  2012cited by this paper
• IL-12 family cytokines: immunological playmakers

  2012cited by this paper
• Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.

  2012cited by this paper
• Regulatory B Cells Control T Cell Autoimmunity Through IL-21-Dependent Cognate Interactions

  2012cited by this paper
• Dendritic cells modifi cation during sublingual immunotherapy in children with allergic symptoms to house dust mites

  2011cited by this paper
• Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis.

  2011cited by this paper
• Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis.

  2011cited by this paper
• Helminth-induced CD 19 1 CD 23 hi B cells modulate experimental allergic and autoimmune inflammation

  2010cited by this paper
• IL-35-mediated induction of a potent regulatory T cell population

  2010cited by this paper
• Birch Pollen Immunotherapy Leads to Differential Induction of Regulatory T Cells and Delayed Helper T Cell Immune Deviation

  2010cited by this paper
• Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3‐expressing cells and elevated allergen‐specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E‐facilitated allergen binding to B cells

  2010cited by this paper
• House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.

  2009cited by this paper
• Cells Do Not Constitutively Express IL-35 Regulatory T + Foxp3+ CD25+ Human CD4

  2008cited by this paper
• IL‐35 is a novel cytokine with therapeutic effects against collagen‐induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells

  2007cited by this paper
• Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.

  2007cited by this paper
• The inhibitory cytokine IL-35 contributes to regulatory T-cell function

  2007cited by this paper
• Grass Pollen Immunotherapy Induces an Allergen-Specific IgA2 Antibody Response Associated with Mucosal TGF-β Expression1

  2007cited by this paper
• Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.

  2003cited by this paper
• Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.

  2001cited by this paper
• Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

  1996cited by this paper
• Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study.

  1982cited by this paper

• The role and mechanism of IL‑35 in myasthenia gravis (Review).

  2026cites this paper
• Expression and significance of IL-27 and IL-35 in orbital fat in patients with severe TAO

  2026cites this paper
• Multiomics approach to evaluating personalized biomarkers of allergen immunotherapy.

  2025cites this paper
• IL35 modulates HBV-related HCC progression via IL6-STAT3 signaling

  2025cites this paper
• IL-35 modulates Tfh2 and Tfr cell balance to alleviate allergic rhinitis

  2025cites this paper
• Immunomodulatory effects of iTr35 cell subpopulation and its research progress

  2024cites this paper
• Vaccination against infectious agents and allergen-specific immunotherapy: A critical analysis

  2023cites this paper
• Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells

  2023cites this paper
• Mechanisms and predictive biomarkers of allergen immunotherapy in the clinic.

  2023cites this paper
• Efficacy and immunological changes of sublingual immunotherapy in pediatric allergic rhinitis

  2023cites this paper
• Clinical and Experimental Treatment of Allergic Asthma with an Emphasis on Allergen Immunotherapy and its Mechanisms.

  2023cites this paper
• Elevated IL-35 level and iTr35 subset increase the bacterial burden and lung lesions in Mycobacterium tuberculosis-infected mice

  2022cites this paper
• Sustained impact of subcutaneous immunotherapy among patients with allergic rhinitis who experienced treatment delay due to the COVID‐19 pandemic: A multicenter, two‐arm, real‐world study

  2022cites this paper
• Introduction to Mechanisms of Allergic Diseases

  2022cites this paper
• At Embryo Implantation Site IL-35 Secreted by Trophoblast, Polarizing T Cells towards IL-35+ IL-10+ IL-4+ Th2-Type Cells, Could Favour Fetal Allograft Tolerance and Pregnancy Success

  2022cites this paper
• A pathogenic integrated view explaining the different endotypes of asthma and allergic disorders

  2022cites this paper
• Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time

  2022cites this paper
• Immunology of allergen immunotherapy

  2022cites this paper
• Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update

  2022cites this paper
• B Cell Functions in the Development of Type I Allergy and Induction of Immune Tolerance.

  2021cites this paper
• Peptide Allergen Immunotherapy: A New Perspective in Olive-Pollen Allergy

  2021cites this paper
• One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence

  2021cites this paper
• CD25+ B Cells Produced IL-35 and Alleviates Local Inflammation during Experimental Periodontitis.

  2021cites this paper
• Treatment Approaches to Food Allergy.

  2021cites this paper
• Characteristics of tissue–resident ILCs and their potential as therapeutic targets in mucosal and skin inflammatory diseases

  2021cites this paper
• Lower Functional and Proportional Characteristics of Cord Blood Treg of Male Newborns Compared with Female Newborns

  2021cites this paper
• Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies

  2020cites this paper
• Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy: What Is New?

  2020influential citation
• Correlation between miR-223 and IL-35 and their regulatory effect in children with allergic rhinitis.

  2020cites this paper
• Immunoregulatory effects of Imuno TF® (transfer factors) on Th1/Th2/Th17/Treg cytokines

  2020cites this paper
• EAACI Allergen Immunotherapy User's Guide

  2020cites this paper
• IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy.

  2020cites this paper
• State‐of‐the‐art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)

  2019cites this paper